Pharmaceuticals in the Trade Related Aspects of the Intellectual Property Rights (TRIPS) Agreement of the World Trade Organization - A Briefing on Trips
(2000; 20 pages)
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Afficher le document1. What is WTO and what is the TRIPS Agreement?
Afficher le document2. What are the implications of the TRIPS Agreement on patents for pharmaceutical products?
Afficher le document3. How long are patented drugs protected by the TRIPS Agreement?
Afficher le document4. Does the TRIPS Agreement strengthen the monopoly patenting of processes?
Afficher le document5. What are the impacts of the TRIPS Agreement on prices and availability of pharmaceutical products?
Afficher le document6. What can Member States do to counteract the impact of TRIPS on drug prices?
Afficher le document7. The balance between the protection of intellectual property rights and public policy objectives
Afficher le document8. When will the TRIPS Agreement be applied?
Afficher le document9. What is WHO’s view and position on WTO/TRIPS Agreement?
Afficher le document10. What are the recommendations for Member States?
 

5. What are the impacts of the TRIPS Agreement on prices and availability of pharmaceutical products?

• Twenty years of monopoly on a pharmaceutical product will enable the patent holder to keep the price of the patented drugs high.

• Copies of the drugs under patent either produced locally or imported should be banned from the market.

• The generic equivalents would come onto the market only after the expiry of the patent of a patented drug. During this period of patent protection, there will be no cheaper alternatives.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013